First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts

Hematological Oncology

Volumn 25, Issue 3, 2007, Pages 143-147

  Andrikovics, Hajnalka ^a   Nahajevszky, Sarolta ^a   Szilvási, Anikó ^a   Bors, András ^a   Ádám, Emma ^a   Kozma, András ^a   Kajtár, Béla ^b   Barta, Anikó ^c   Poros, Anna ^a   Tordai, Attila ^a  

^a NATIONAL MEDICAL CENTER   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c Szent Lászlo Municipal Hospital   (Hungary)

Author keywords

BCR ABL e1a2 and e19a2 breakpoints; Chronic myelogenous leukaemia; Imatinib

Indexed keywords

ANTHRACYCLINE; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; HYDROXYUREA; IDARUBICIN; IMATINIB; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER SURVIVAL; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; FEMALE; FEVER; HUMAN; LABORATORY TEST; MALE; PRIORITY JOURNAL; RADIATION DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC AGENTS; CHROMOSOME BREAKAGE; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 34848820546     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.822     Document Type: Article

References (21)

1. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet. Blood 2006; 108: 1809-1820.
2. Ito T, Tanaka H, Tanaka K, et al. Insertion of a genomic fragment of chromosome 19 between BCR intron 19 and ABL intron 1a in a chronic myeloid leukaemia patient with microBCR-ABL (e19a2) transcript. Br J Haematol 2004; 126: 752-753.
3. Ravandi F, Cortes J, Albitar M, et al. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol 1999; 107: 581-586.
4. Hur M, Song EY, Kang SH, et al. Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia. Ann Hematol 2002; 81: 219-223.
5. Ohsaka A, Shiina S, Kobayashi M, Kudo H, Kawaguchi R. Philadelphia chromosome-positive chronic myeloid leukemia expressing p190 (BCR-ABL). Intern Med 2002; 41: 1183-1187.
6. Nakaseko C, Sakaida E, Uehara T, et al. Successful cord blood transplantation in a minor BCR-ABL+ CML patient who had been in lymphoid blast crisis at presentation. Bone Marrow Transplant 2006; 37: 535-536.
7. Rotoli B, Pane F, Salvatore F, et al. The e19a2 bcr/abl breakpoint in acute lymphoblastic leukaemia. Br J Haematol 2000; 110: 493-496.
8. Verstovsek S, Lin H, Kantarjian H, et al. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer 2002; 94: 2416-2425.
9. Mittre H, Leymarie P, Macro M, et al. A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction. Is it really a distinct disease? Blood 1997; 89: 4239-4241.
10. Lee JJ, Kim HJ, Kim YJ, et al. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts. Leukemia 2004; 18: 1539-1540.
11. Wang L, Seale J, Woodcock BE, et al. e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts. Leukemia 2002; 16: 1562-1563.
12. Ohsaka A, Hoshino S, Kobayashi M, et al. Blast crisis of Philadelphia chromosome-positive chronic myeloid leukaemia carrying micro-bcr breakpoint (e19a2 and e191a). Br J Haematol 2002; 118: 251-254.
13. Polak J, Koza V, Cetkovsky P, et al. An accelerrated-phase CML patient with e19a2 junction of BCR/ABL gene: the first case of transplanted CML with micro bcr. Bone Marrow Transplant 2000; 25: 1109-1110.
14. Haskovec C, Ponzetto C, Polak J, et al. P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. Br J Haematol 1998; 103: 1104-1108.
15. Bertorelle R, Bonaldi L, Bianchini E, et al. The e19a2 BCR/ABL fusion transcript with additional chromosomal aberrations on a new case of chronic myeloid leukemia (CML) of mild type. Leukemia 2001; 15: 2003-2004.
16. Nakamura F, Ogawa S, Izutsu K, et al. Should young patients with e19a2 type BCR/ABL rearrangement undergo stem cell transplantation? Leuk Lymphoma 2003; 44: 381-382.
17. Boeckx N, Jansen MW, Haskovec C, et al. Identification of e19a2 BCR-ABL fusions (mu-BCR breakpoints) at the DNA level by ligation-mediated PCR. Leukemia 2005; 19: 1292-1295.
18. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384.
19. Martinelli G, Iacobucci I, Soverini S, et al. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. Hematol Oncol 2006; 24: 196-204.
20. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
21. Popovici C, Cailleres S, David M, et al. e6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib. Leuk Lymphoma 2005; 46: 1375-1377.